A new study by Lo et al. presents a novel immunosuppressive combination in a clinically relevant primate model of renal allografting. Using belatacept, a fusion protein that inhibits CD28–CD80/CD86 co-stimulation, plus the mammalian target of rapamycin inhibitor sirolimus, they were able to achieve rejection-free allograft survival without the induction of memory T cells or alloantibody.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Larsen, C. P. et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5, 443–453 (2005).
Vincenti, F. et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am. J. Transplant. 12, 210–217 (2012).
Larsen, C. P. et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434–438 (1996).
Kirk, A. D. et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci. USA 94, 8789–8794 (1997).
Lo, D. J. et al. Belatcept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am. J. Transplant. 13, 320–328 (2013).
Stegall, M. D. & Gloor, J. M. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr. Opin. Organ. Transplant. 15, 8–10 (2010).
Stock, P. & Kirk, A. D. The risk and opportunity of homeostatic repopulation. Am. J. Transplant. 11, 1349–1350 (2011).
Lowe, M. C. et al. Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. Am. J. Transplant. 13, 312–319 (2013).
Kirk, A. D. et al. Kidney transplantation using alemtuzumab induction and belatacept/sirolimus maintenance therapy. Am. J. Transplant. 11 (Suppl. 2), S45 (2011).
Bour-Jordan, H. & Bluestone, J. A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol. Rev. 229, 41–66 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Barth, R., Bromberg, J. The promise of co-stimulatory blockade in transplantation. Nat Rev Nephrol 9, 189–190 (2013). https://doi.org/10.1038/nrneph.2013.37
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.37
